GSK has announced that the US FDA has accepted for priority review a supplemental Biologics License Application for Jemperli ...
A July 2026 Leerink Partners report named Carterra a core enabling technology in the growing Lab‑in‑the‑Loop market. The ...
Avulux has received De Novo marketing authorisation from the FDA, establishing the first recognised device classification for ...
Erasca has been granted Fast Track Designation by the FDA for ERAS‑0015, an oral pan‑RAS molecular glue being developed for ...
FairJourney Bio has published a peer‑reviewed study in mAbs describing a novel antibody‑engineering approach designed to ...
Teva Pharmaceuticals has announced that the US Food and Drug Administration has accepted the new drug application for ...
HUTCHMED has reported positive high‑level results from the Saffron phase 3 trial evaluating Orpathys (savolitinib) plus ...
AC Immune has announced encouraging preliminary findings from its phase 1 first‑in‑human study of ACI‑19764, an orally ...
VarmX has enrolled the first participant in its global phase 3 EquilibriX S trial evaluating VMX C001 for the rapid ...
The MHRA’s position is that MBMPs fall within the scope of the existing UK medicines regulatory framework set out in the ...
Androlabs has appointed EffRx Pharmaceuticals as its commercial partner in Switzerland for Testavan, a testosterone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results